SBIR-STTR Award

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis with an estimated 2 billion people currently infected worldwide and several million new cases detected each year. Current methods of diagnosis are slow and/or unreliable. Therefore, new diagnostics are urgently needed to address the global tuberculosis burden and improve control programs. The goal of this application is to develop a simple, rapid, accurate, and cost-effective serological test for active tuberculosis that can be utilized in resource-limited settings. This test will use the innovative Dual Path Platform (DPPTM) technology developed and patented by the investigator Chembio Diagnostic Systems, Inc., and selected antigens from a large panel of novel recombinant antigens identified at the Infectious Disease Research Institute (IDRI). The proposed assay will detect specific antibodies and demonstrate improved sensitivity and specificity over the existing rapid tests. Assay improvements will result from both the Chembio proprietary immunoassay advances and the extensive portfolio of novel antigens available from IDRI. The test will be developed for point-of-care or field application, with results produced within 15 minutes of addition of blood sample to the assay. In addition to the visual reading, there will be an option for automated readout of the test result. The two specific aims of the Phase I studies will result in a prototypic test and determine the feasibility of proceeding into Phase II work: 1. Define the selection of tuberculosis antigens for a DPP test prototype. Using a large panel of novel antigens discovered by IDRI and efficient screening method developed by Chembio (termed MAPIA) the most seroreactive antigens recognized by serum antibodies will be identified. 2. Develop a prototype DPP test for tuberculosis. Cocktails of the most seroreactive antigens will be designed and components of the DPP assay format will be optimized to develop a prototype diagnostic test to detect the greatest number of tuberculosis patients. The feasibility of proceeding to Phase II with the DPP prototype will be established if: 1) the test sensitivity is >80% and 2) the test specificity is >95%. No commercial product for rapid, point-of-care TB diagnosis with such functional and performance characteristics is available on the market. Thus, developing the proposed DPP-based test for tuberculosis will be a major improvement. PUBLIC HEALTH RELEVANCE Tuberculosis remains one of the leading causes of mortality due to infectious disease worldwide. The current methods for diagnosis of tuberculosis are time-consuming, complex and laborious, and/or too expensive for routine use in resource-limited settings where most of patients live. The delayed or missed diagnosis leads to spreading of infection, progression of disease, and increased mortality. The research proposed here aims at developing a simple and rapid point-of-care diagnostic test that would improve control programs by helping accurately detect new cases of tuberculosis, enabling timely antibiotic therapy, and preventing disease transmission.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis with an estimated two billion people currently infected worldwide and over nine million new cases detected annually worldwide. This is the largest killer of patients with HIV/AIDS. Current methods of diagnosis are complex, time-consuming, unreliable or unaffordable for most countries where the disease presents a significant public health threat. New diagnostics are critically needed to address the global tuberculosis burden and improve control programs. Our Phase I studies have clearly demonstrated the feasibility of developing a rapid and accurate test for tuberculosis. In collaboration with the Infectious Disease Research Institute, scientists at Chembio Diagnostic Systems, Inc. have identified a set of novel seroreactive antigens, designed several highly performing polyepitope fusion proteins, and applied the selected antigens in the Chembio's innovative immunoassay format, the Dual Path Platform (DPP(R)), with proven high accuracy of rapid serodiagnosis. We found that a DPP test prototype had a sensitivity of 81% and specificity of 95% in evaluations with serum samples obtained from culture-confirmed patients with active pulmonary tuberculosis from endemic regions in Brazil and Indonesia. In this Phase II application we propose to complete development and evaluation of the rapid diagnostic test for tuberculosis which will have required performance and operational characteristics. The specific aims are to: 1) optimize assay design, 2) determine diagnostic test performance, and 3) validate test production protocols in preparation for regulatory approval. We expect that the proposed DPP assay will demonstrate improved sensitivity and specificity over the existing rapid tests and will be applicable for expedited diagnosis of tuberculosis worldwide.

Public Health Relevance:
Tuberculosis remains one of the leading causes of mortality due to infectious disease worldwide. The current methods for diagnosis of tuberculosis are time-consuming, complex and laborious, and/or too expensive for routine use in resource-limited settings where most of patients live. The delayed or missed diagnosis leads to spreading of infection, progression of disease, and increased mortality. The research proposed here aims at developing a simple and rapid (20 minutes) point-of-care diagnostic test that would improve control programs by helping accurately detect new cases of tuberculosis, enabling timely antibiotic therapy, and preventing disease transmission. In addition to the visual reading, there will be an option for automated readout of the test result. The proposed assay will be fully validated and evaluated with serum samples from six countries representing various geographical areas and epidemiological setting associated with tuberculosis. These studies will demonstrate superior sensitivity and specificity as well as improved operational characteristics over the existing technologies.

Thesaurus Terms:
Aids/Hiv;Aids/Hiv Problem;Atgn;Address;Antibiotic Therapy;Antibiotic Treatment;Antibodies;Antigens;Area;Assay;Bioassay;Biologic Assays;Biological Assay;Blood Sample;Blood Serum;Blood Specimen;Brazil;Cell Communication And Signaling;Cell Signaling;Characteristics;Chimera Protein;Chimeric Proteins;Chronic;Clinical Evaluation;Clinical Testing;Collaborations;Collection;Communicable Diseases;Complex;Country;Detection;Development;Diagnosis;Diagnostic;Diagnostic Tests;Disease;Disease Progression;Disorder;East Indies;Epidemiology;Evaluation;Fusion Protein;Geographic Area;Geographic Locations;Geographic Region;Geographical Location;Hiv/Aids;Hiv/Aids Problem;Immune Response;Immunoassay;Indonesia;Infection;Infectious Disease Pathway;Infectious Diseases;Infectious Diseases / Laboratory;Infectious Diseases Research;Infectious Diseases And Manifestations;Infectious Disorder;Intracellular Communication And Signaling;Life;Lung Tb;Lung Tuberculosis;M. Tb;M. Tuberculosis;M.Tb;M.Tuberculosis;Malay Archipelago;Mesh Descriptors Class 4;Methods;Mortality;Mortality Vital Statistics;Mycobacterium Tuberculosis;Netherlands East Indies;Patients;Performance;Phase;Preparation;Prevalence;Printing;Procedures;Production;Programs (Pt);Programs [publication Type];Protocol;Protocols Documentation;Public Health;Pulmonary Tb;Pulmonary Tuberculosis;Quality Control;Reading;Recombinants;Research;Research Institute;Research Resources;Resources;Sampling;Scientist;Sensitivity And Specificity;Serodiagnoses;Serologic;Serological;Serological Diagnosis;Serum;Signal Transduction;Signal Transduction Systems;Signaling;Specificity;System;System, Loinc Axis 4;Technology;Test Result;Testing;Time;Tuberculosis;Tuberculosis, Pulmonary;Validation;Visual;Whblood;Whole Blood;Antibody;Biological Signal Transduction;Clinical Test;Communicable Disease Transmission;Design;Designing;Diagnostic Serology;Disease /Disorder;Disease Transmission;Disease/Disorder;Disseminated Tb;Disseminated Tuberculosis;Experience;Geographic Site;Host Response;Immunogen;Immunoresponse;Improved;Infectious Disease Transmission;Innovate;Innovation;Innovative;New Diagnostics;Next Generation Diagnostics;Novel;Novel Diagnostics;Phase 1 Study;Phase 2 Study;Point Of Care;Point-Of-Care Diagnostics;Prevent;Preventing;Programs;Prototype;Public Health Medicine (Field);Research Clinical Testing;Treatment Of Bacterial Diseases;Treatment Of Bacterial Infectious Disease;Tuberculous Spondyloarthropathy